SCHEMBL15828228

SCHEMBL15828228

Nc1ncnc2c1ncn2[C@@H]1O[C@](F)(COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX1 P51575 4/20 0.63
▸ P2RX3 P56373 4/20 0.63
▸ P2RX2 Q9UBL9 2/20 0.63
▸ P2RY1 P47900 9/20 0.62
▸ P2RY2 P41231 6/20 0.62
▸ P2RY11 Q96G91 2/20 0.62
▸ P2RX4 Q99571 3/20 0.60
▸ SRC P12931 2/20 0.60
▸ SMN1; SMN2 Q16637 2/20 0.60
▸ ALDH1A1 P00352 1/20 0.60
▸ RNASEL Q05823 1/20 0.58
▸ TRPM2 O94759 2/20 0.56
▸ MACROD2 A1Z1Q3 1/20 0.56
▸ SIRT6 Q8N6T7 1/20 0.56
▸ MACROD1 Q9BQ69 1/20 0.56
▸ DNPH1 O43598 1/20 0.55
▸ PRKAB2 O43741 1/20 0.55
▸ LDHA P00338 1/20 0.55
▸ ADRB2 P07550 1/20 0.55
▸ FBP1 P09467 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15828310 1.00 P2RX1 (0.63) P2RX1P2RX3P2RX2P2RY1P2RY2
SCHEMBL17384915 0.87 P2RY1 (0.64) P2RX1P2RX3P2RX2P2RY1P2RY2
SCHEMBL31398396 0.87 P2RX1 (0.63) P2RX1P2RX3P2RX2P2RY1P2RY2
SCHEMBL16998340 0.87 P2RX1 (0.60) P2RX1P2RX3P2RX2P2RY1P2RY2
SCHEMBL15828284 0.86 P2RX3 (0.47) P2RX1P2RX3P2RX2P2RY1P2RY2
SCHEMBL15828312 0.86 P2RX3 (0.47) P2RX1P2RX3P2RX2P2RY1P2RY2
SCHEMBL16373878 0.86 P2RX1 (0.61) P2RX1P2RX3P2RX2P2RY1P2RY2
SCHEMBL21465279 0.85 P2RX1 (0.60) P2RX1P2RX3P2RX2P2RY1P2RY2
SCHEMBL17641457 0.85 P2RX1 (0.60) P2RX1P2RX3P2RX2P2RY1P2RY2
SCHEMBL31228119 0.85 P2RY1 (0.46) P2RX1P2RX3P2RX2P2RY1P2RY2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9211300-B2 4′-fluoro nucleosides for the treatment of HCV IDENIX PHARMACEUTICALS LLC (US) 2015-12-15 — — US disclosed
US-20140178338-A1 4'-FLUORO NUCLOSIDES FOR THE TREATMENT OF HCV UNIVERSITE DE MONTPELLIER (FR) 2014-06-26 — — US disclosed
WO-2014099941-A1 4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV IDENIX PHARMACEUTICALS, INC. (US) 2014-06-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140178338-A1 4'-FLUORO NUCLOSIDES FOR THE TREATMENT OF HCV FBL, HNRNPLL, SLC28A1 P2RX1 1842/4885P2RX3 1685/4885P2RX2 2198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback